Silverman Joshua
Chief Executive Officer
Silverman Joshua has filed 12 SEC Form 4 filings (19 transaction rows) across 4 companies, including FABC, QCLS, PTPI, with disclosures dating back to 2025. 10 of those filings fall inside the rolling window. Most recent filing: Oct 16, 2026.
On the most recent filing, Silverman Joshua is listed as CEO and President at PharmaCyte Biotech, Inc. Inside the rolling window, Silverman Joshua reported 3 open-market purchases totaling $80K in PMCB and no open-market sales. The largest disclosed transaction in the window is a purchase of 40,000 PMCB shares on Jan 7, 2026, worth $33K.
Companies traded
Insider Buying
$80K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
4
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Silverman Joshua made?
Silverman Joshua has filed 12 SEC Form 4 filings (19 transaction rows) across 4 companies, including FABC, QCLS, PTPI since 2025.
Which companies does Silverman Joshua trade?
Silverman Joshua has filed SEC Form 4 disclosures for 4 companies, including FABC, QCLS, PTPI.
When was Silverman Joshua's most recent SEC Form 4 filing?
Silverman Joshua's most recent SEC Form 4 filing on Tracefour is dated Oct 16, 2026.
What is Silverman Joshua's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Silverman Joshua is listed as Chief Executive Officer.
What is Silverman Joshua's total buy and sell value in the current window?
Inside the rolling retention window, Silverman Joshua bought $80K and sold $0 based on SEC Form 4 filings.
What was Silverman Joshua's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 40,000 PMCB shares on 2026-01-07, worth $33K, per SEC Form 4 filings.